

HPV Vaccine: A Crucial Tool in the Global Fight Against Cancer - A Comprehensive Review

Dr. Amit Sachdeva and Nasim Ahmed

¹Assistant Professor, Department of Community Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India. Email: dramitsachdeva2410@gmail.com

²Independent Researcher, Guwahati Assam, India Email: nasim@iarcon.org

Received: Dec. 04, 2025; Revised: Jan. 26, 2026; Accepted: Feb. 17, 2026; Published: Mar. 30, 2026

Under a Creative Commons license Doi: 10.47310/medlet.2026.v0301.005

Abstract: The Human Papillomavirus (HPV) vaccine has emerged as a crucial tool in combating HPV-related diseases, including cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers, as well as genital warts. This review provides a comprehensive analysis of the HPV vaccine, detailing its development, effectiveness, safety, and vaccination schedules. It also examines global statistics, with a particular focus on the status of HPV vaccination in India and the state of Himachal Pradesh. The vaccine's efficacy in preventing high-risk HPV infections and related cancers is supported by extensive clinical trial data and real-world evidence, showcasing significant reductions in disease incidence among vaccinated populations. Despite the proven benefits, challenges such as cost, cultural perceptions, and healthcare access continue to hinder widespread adoption, particularly in low- and middle-income countries. Recent advancements, including the development of therapeutic vaccines, hold promise for future HPV-related disease prevention and treatment. In India and Himachal Pradesh, targeted initiatives and community engagement are essential to overcome barriers and ensure broader vaccine coverage. This review underscores the importance of continued efforts to improve vaccine accessibility, reduce costs, and address cultural barriers to achieve global success in the fight against HPV-related diseases.

Keywords: HPV vaccine, cervical cancer prevention, global health, vaccination challenges, therapeutic vaccines

INTRODUCTION

Human papillomavirus (HPV) is one of the most common sexually transmitted infections globally, affecting both men and women. The virus is known to cause various cancers, including cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers, as well as genital warts. The introduction of the HPV vaccine has been a significant milestone in the fight against HPV-related diseases. This review article explores the details of the HPV vaccine, including its effectiveness, vaccination schedules, recent statistics, and the status of HPV vaccination in India and Himachal Pradesh.[1-5]

Understanding HPV and Its Impact

HPV is a group of more than 200 related viruses, with more than 40 types spread through direct sexual contact. While most HPV infections are asymptomatic and resolve on their own, persistent infections with high-risk HPV types can lead to cancer. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases worldwide.[6-8]

Global Burden of HPV-Related Diseases

Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. The majority of these cases occur in low- and middle-income countries, where access to screening and treatment is limited. Other HPV-related cancers, such as oropharyngeal and anal cancers, are also on the rise, particularly in high-income countries.[9-11]

HPV Vaccine: Development and Types

The HPV vaccine was developed to prevent infections from the most common high-risk HPV types. There are three main types of HPV vaccines:

- Gardasil (Quadrivalent Vaccine): Protects against HPV types 6, 11, 16, and 18.

How to cite this Content: Sachdeva, Amit, and Nasim Ahmed. "HPV Vaccine: A Crucial Tool in the Global Fight Against Cancer - A Comprehensive Review" *Medical Letter*, vol. 3, no. 1, 2026, pp. 25–28.

- Cervarix (Bivalent Vaccine): Protects against HPV types 16 and 18.
- Gardasil 9 (Nonavalent Vaccine): Protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

Vaccination Schedule and Recommendations

The Centers for Disease Control and Prevention (CDC) recommends the HPV vaccine for preteens aged 11 to 12 years, but it can be administered as early as age 9. The vaccine is given in a series of shots:

- Two-dose schedule: For children starting the series before their 15th birthday, the second dose is given 6 to 12 months after the first dose.
- Three-dose schedule: For those starting the series at age 15 or older, and for immunocompromised individuals, the second dose is given 1 to 2 months after the first dose, and the third dose is given 6 months after the first dose.

Effectiveness and Safety

The HPV vaccine has been shown to be highly effective in preventing infections with the HPV types it targets. Studies have demonstrated a significant reduction in the incidence of HPV-related diseases, including cervical cancer and genital warts, in vaccinated populations.[12-14]

Clinical Trial Results

Clinical trials have shown that the HPV vaccines are highly effective in preventing cervical infection with the types of HPV they target when given before first exposure to the virus. The vaccines have also been found to reduce infections in other tissues that HPV infects, including the anus and oral region. Trials and real-world data from population-based studies have now demonstrated that the vaccines greatly reduce the risk of precancers and cancers of the cervix, vagina, and vulva in vaccinated women.[14,15]

Safety Profile

The vaccine is also considered safe, with the most common side effects being mild and temporary, such as pain at the injection site, fever, dizziness, and nausea. Serious side effects are rare. More than 12 years of safety monitoring show that the vaccines have caused no serious side effects. The most common problems have been brief soreness and other local symptoms at the injection site, similar to those experienced with other vaccines.[16,17]

Recent Statistics

Global Statistics

According to the World Health Organization (WHO), as of 2024, more than 100 countries have implemented HPV vaccination programs. The coverage rates vary widely, with high-income countries achieving higher coverage compared to low- and middle-income countries.[18,19]

United States

In the United States, data from the 2022 National Health Interview Survey indicated that 38.6% of children aged 9–17 years had received one or more doses of the HPV vaccine. The vaccination coverage increased with age, parental education, and family income. Girls were more likely to be vaccinated than boys, and children with private health insurance had higher vaccination rates compared to those with Medicaid or no insurance.[18-20]

Status of HPV Vaccination in India

National Efforts

India has been making concerted efforts to reduce the burden of cervical cancer through HPV vaccination. The country records one cervical cancer death every seven minutes, highlighting the urgent need for preventive measures. Although the HPV vaccine was introduced in India in 2008, it is yet to be included in the country's universal immunization program.

In 2016, the states of Punjab and Sikkim introduced HPV vaccination programs, achieving high coverage rates of 97% among targeted girls. In 2024, the Indian government announced plans for a national drive to vaccinate girls aged 9 to 14 years against HPV, as part of its broader strategy to eliminate cervical cancer. [4,6]

Challenges and Cultural Perceptions

The cost of the HPV vaccine, approximately 3,000 rupees (US\$36) per dose, and cultural perceptions surrounding reproductive health have been significant barriers to widespread adoption. Efforts to educate communities and reduce stigma are crucial for the success of the vaccination program.

Status of HPV Vaccination in Himachal Pradesh

Himachal Pradesh, a state known for its challenging terrain and dispersed population, faces unique challenges in implementing HPV vaccination programs. Despite these challenges, the state has made significant strides in improving healthcare access and awareness.

Current Initiatives

Himachal Pradesh has been proactive in addressing public health issues, including HPV vaccination. The state government has been working to integrate HPV vaccination into its broader public health strategies, focusing on awareness campaigns and community engagement.

Coverage and Challenges

The coverage of HPV vaccination in Himachal Pradesh is still limited, with efforts concentrated in urban areas. Rural and remote regions face significant barriers, including limited access to healthcare facilities and cultural resistance. Addressing these challenges requires targeted interventions, including mobile vaccination units and community-based education programs.

Innovative Developments in HPV Vaccines

Recent advancements in HPV vaccine development include the creation of therapeutic vaccines that could potentially treat existing HPV infections and precancerous lesions. These vaccines aim to boost the body's immune response to clear high-risk HPV strains or abnormal cells.

CONCLUSION

The HPV vaccine represents a significant advancement in the prevention of HPV-related diseases, including cervical cancer. While global efforts have achieved notable success, challenges remain, particularly in low- and middle-income countries like India. Continued efforts to improve vaccine access, reduce costs, and address cultural barriers are essential for the success of HPV vaccination programs. In Himachal Pradesh, targeted interventions and community engagement are crucial to overcoming unique challenges and ensuring widespread vaccination coverage.

REFERENCES

1. Centers for Disease Control and Prevention et al; "Human Papillomavirus Vaccination Coverage Among Adolescents, 2022" 1.1 (2024) Pp1-2, Available from: <https://www.cdc.gov/nchs/products/databriefs/db495.htm>
2. World Health Organization et al; "Vaccines to Treat Human Papillomavirus Could Be a Significant Innovation in the Fight Against Cervical Cancer" 1.1 (2024) Pp1-2, Available from: <https://www.who.int/news/item/03-07-2024-vaccines-to-treat-human-papillomavirus-could-be-a-significant-innovation-in-the-fight-against-cervical-cancer>
3. Cleveland Clinic et al; "HPV Vaccine: Age, Schedule, Importance & Side Effects" 1.1 (2023) Pp1-2, Available from: <https://my.clevelandclinic.org/health/treatments/21613-hpv-vaccine>
4. Padma et al; "India Resolves to Reduce Cervical Cancer by Vaccinating Girls" 1.1 (2024) Pp1-2, Available from: <https://www.gavi.org/vaccineswork/india-resolves-reduce-cervical-cancer-vaccinating-girls>
5. Palepu et al; "India HPV Shot Can Curb Cervical Cancer" 1.1 (2024) Pp1-2, Available from: <https://www.bloomberg.com/tosv2.html?url=L25ld3MvYXJ0aWNsZXRMvMjAyNC0wNi0yMS9pbmRpYS1pcy1ncm91bmQtemVyby1pb1iYXR0bGluZy1hLWNhbmNlci10aGF0LWtpbGxzLWEtd29tYW4tZXZlcnkN1taW51dGVz&uuiid=1b43d312-3024-11ef-ae7b-356bb40edc7f>
6. The Hindu et al; "A Bold Step Towards a Cervical Cancer-Free Future" 1.1 (2024) Pp1-2, Available from: <https://www.thehindu.com/opinion/lead/a-bold-step-towards-a-cervical-cancer-free-future/article67925836.ece>

7. World Health Organization et al; "Wave of New Commitments Marks Historic Step Towards the Elimination of Cervical Cancer" 1.1 (2024) Pp1-2, Available from: <https://www.who.int/news/item/05-03-2024-wave-of-new-commitments-marks-historic-step-towards-the-elimination-of-cervical-cancer>
8. World Health Organization et al; "Human Papillomavirus Vaccines: WHO Position Paper, December 2022" 1.1 (2022) Pp1-2, Available from: <https://www.who.int/publications/i/item/who-wer9750-645-672>
9. Schiller et al; "A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines" 30.Suppl 5 (2012) PpF123-138, doi <https://doi.org/10.1016/j.vaccine.2012.05.089>
10. Bruni et al; "Global Estimates of Human Papillomavirus Vaccination Coverage by Region and Income Level: A Pooled Analysis" 4.7 (2016) Ppe453-463, doi [https://doi.org/10.1016/S2214-109X\(16\)30099-7](https://doi.org/10.1016/S2214-109X(16)30099-7)
11. de Martel et al; "Worldwide Burden of Cancer Attributable to HPV by Site, Country and HPV Type" 141.4 (2017) Pp664-670, doi <https://doi.org/10.1002/ijc.30716>
12. Ferlay et al; "Global Cancer Observatory: Cancer Tomorrow" 1.1 (2024) Pp1-2, Available from: <https://gco.iarc.fr/tomorrow>
13. Markowitz et al; "Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)" 63.RR-05 (2014) Pp1-30
14. World Health Organization et al; "Human Papillomavirus and Related Diseases Report" 1.1 (2024) Pp1-2, Available from: <https://www.who.int/hpvcentre>
15. Wikipedia et al; "HPV Vaccine" 1.1 (2023) Pp1-2, Available from: https://en.wikipedia.org/wiki/HPV_vaccine
16. ScienceDirect et al; "Epidemiology and Burden of HPV-Related Disease" 1.1 (2023) Pp1-2, Available from: <https://www.sciencedirect.com/science/article/abs/pii/S1521693417301244>
17. PubMed et al; "Cancer Statistics, 2024" 1.1 (2024) Pp1-2, Available from: <https://pubmed.ncbi.nlm.nih.gov/38230766/>
18. National Cancer Institute et al; "Human Papillomavirus (HPV) Vaccines" 1.1 (2023) Pp1-2, Available from: <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet>
19. American College of Obstetricians and Gynecologists et al; "Human Papillomavirus Vaccination" 1.1 (2020) Pp1-2, Available from: <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/08/human-papillomavirus-vaccination>
20. World Health Organization et al; "Human Papillomavirus and HPV Vaccines" 1.1 (2023) Pp1-2, Available from: <https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-%28HPV%29>